Group One Trading
HRTX icon

Group One Trading’s Heron Therapeutics HRTX Stock Holding History

Group One Trading’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.2K Sell
4,000
-21,800
-84% -$25.3K ﹤0.01% 6904
2025
Q4 		$33.5K Buy
25,800
+17,100
+197% +$21.1K ﹤0.01% 5926
2025
Q3 		$11K Sell
8,700
-6,900
-44% -$10.9K ﹤0.01% 7112
2025
Q2 		$32.3K Sell
15,600
-957,400
-98% -$1.96M ﹤0.01% 5928
2025
Q1 		$2.14M Sell
973,000
-28,200
-3% -$54.7K 0.01% 1755
2024
Q4 		$1.53M Buy
1,001,200
+959,000
+2,273% +$1.55M ﹤0.01% 2151
2024
Q3 		$84K Buy
42,200
+200
+0.5% +$478 ﹤0.01% 4314
2024
Q2 		$147K Sell
42,000
-867,100
-95% -$2.66M ﹤0.01% 3654
2024
Q1 		$2.52M Sell
909,100
-65,700
-7% -$165K 0.01% 1324
2023
Q4 		$1.66M Buy
974,800
+33,600
+4% +$37K ﹤0.01% 2027
2023
Q3 		$969K Buy
941,200
+940,600
+156,767% +$1.34M ﹤0.01% 2298
2023
Q2 		$696 Sell
600
-200
-25% -$357 ﹤0.01% 7329
2023
Q1 		$1.21K Sell
800
-1,500
-65% -$3.76K ﹤0.01% 6746
2022
Q4 		$5.75K Sell
2,300
-700
-23% -$2.25K ﹤0.01% 6277
2022
Q3 		$13K Sell
3,000
-8,700
-74% -$34K ﹤0.01% 6336
2022
Q2 		$33K Sell
11,700
-40,600
-78% -$163K ﹤0.01% 5907
2022
Q1 		$299K Buy
52,300
+34,800
+199% +$255K ﹤0.01% 4373
2021
Q4 		$160K Sell
17,500
-56,500
-76% -$577K ﹤0.01% 5298
2021
Q3 		$791K Sell
74,000
-16,700
-18% -$203K ﹤0.01% 3671
2021
Q2 		$1.41M Buy
90,700
+6,700
+8% +$107K ﹤0.01% 3020
2021
Q1 		$1.36M Buy
84,000
+57,000
+211% +$1.02M ﹤0.01% 2879
2020
Q4 		$571K Sell
27,000
-300
-1% -$5.21K ﹤0.01% 3151
2020
Q3 		$405K Sell
27,300
-65,800
-71% -$1.03M ﹤0.01% 3031
2020
Q2 		$1.37M Sell
93,100
-26,200
-22% -$430K 0.01% 1762
2020
Q1 		$1.4M Buy
119,300
+90,200
+310% +$1.7M 0.01% 1274
2019
Q4 		$684K Buy
29,100
+3,300
+13% +$73K ﹤0.01% 2184
2019
Q3 		$477K Buy
25,800
+400
+2% +$7.36K ﹤0.01% 2375
2019
Q2 		$472K Buy
25,400
+4,900
+24% +$97.9K ﹤0.01% 2188
2019
Q1 		$501K Sell
20,500
-19,600
-49% -$513K 0.01% 1938
2018
Q4 		$1.04M Sell
40,100
-47,200
-54% -$1.3M 0.01% 1484
2018
Q3 		$2.76M Buy
87,300
+56,300
+182% +$2.1M 0.02% 933
2018
Q2 		$1.2M Sell
31,000
-49,600
-62% -$1.58M 0.01% 1537
2018
Q1 		$2.23M Buy
80,600
+42,200
+110% +$957K 0.02% 936
2017
Q4 		$695K Sell
38,400
-31,000
-45% -$505K ﹤0.01% 1987
2017
Q3 		$1.12M Buy
69,400
+66,400
+2,213% +$1.04M 0.01% 1470
2017
Q2 		$42K Sell
3,000
-2,700
-47% -$39.1K ﹤0.01% 3589
2017
Q1 		$86K Sell
5,700
-43,100
-88% -$597K ﹤0.01% 3069
2016
Q4 		$639K Buy
48,800
+10,400
+27% +$163K 0.01% 1618
2016
Q3 		$662K Buy
38,400
+600
+2% +$11.1K 0.01% 1600
2016
Q2 		$682K Sell
37,800
-11,700
-24% -$228K 0.01% 1509
2016
Q1 		$940K Buy
49,500
+30,900
+166% +$610K 0.01% 1216
2015
Q4 		$497K Sell
18,600
-384,700
-95% -$10.3M 0.01% 1823
2015
Q3 		$9.84M Buy
403,300
+216,900
+116% +$7.23M 0.14% 154
2015
Q2 		$5.81M Buy
186,400
+124,700
+202% +$2.35M 0.08% 270
2015
Q1 		$898K Buy
+61,700
New +$696K 0.01% 1173
2014
Q4 		– Sell
-1,000
Closed -$8K – 5057
2014
Q3 		$8K Buy
+1,000
New +$9.31K ﹤0.01% 4559

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Group One Trading's HRTX Position: Q1 2026 in Review

Group One Trading reduced its Heron Therapeutics (HRTX) stake by 40% in Q1 2026, selling an estimated $67.6K and leaving 86,809 shares worth $69.5K. The position accounts for ﹤0.01% of the portfolio, ranked #5015.

Group One Trading first reported a position in HRTX in Q2 2014 and has held it in 32 quarters since. The position peaked at $6.15M in Q3 2015. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Group One Trading held 86,809 shares of Heron Therapeutics worth $69.5K as of Q1 2026.
  • Group One Trading sold 58,358 Heron Therapeutics shares in Q1 2026, an estimated $67.6K.
  • Heron Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #5015 holding.
  • Group One Trading first reported a position in Heron Therapeutics in Q2 2014 and has held it in 32 quarters since.
  • Group One Trading's Heron Therapeutics position peaked at $6.15M in Q3 2015.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.